In the cohort of glioblastoma patients where progression-free survival data were available, higher BCR diversity was associated with prolonged progression-free survival, specifically in patients treated with PD-1 inhibitor in the neoadjuvant setting, whereas their treatment-naive counterparts with a scheduled, adjuvant course showed no significant difference (SI Appendix, Fig. S8). This evidence concerns the gene BCR and glioblastoma.